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Abstract: Naturally occurring muraymycin nucleoside antibiot-
ics represent a promising class of novel antimicrobials as they
inhibit MraY, an enzyme involved in bacterial cell wall biosyn-
thesis. The synthesis of muraymycins and their analogues is
challenging as it involves multi-step routes, thus hampering de-
tailed structure-activity relationship (SAR) studies. In this work,
we report a novel solid phase-based synthetic strategy for
accessing muraymycin analogues via a modular approach,
Introduction
Emerging bacteria with resistances against established antibiot-
ics and therapeutic procedures represent a major issue in cur-
rent and future healthcare.[1] Hence, the exploration of novel
antibacterial targets and modes of action is required. One such
promising target that is not addressed by currently used antibi-
otics is the membrane enzyme translocase I (MraY), which is
involved in bacterial cell wall (peptidoglycan) biosynthesis.[2]
Many antibiotics, e.g. the -lactams, block the late extracellular
steps of peptidoglycan formation.[3] However, the preceding in-
tracellular steps (such as the MraY-mediated reaction) remain
largely unexploited for antibacterial development, with the no-
table exception of the clinically used antibiotic fosfomycin in-
hibiting the enzyme MurA.
MraY catalyses the membrane-associated intracellular reac-
tion of UDP-MurNAc-pentapeptide 1 with the membrane an-
chor undecaprenyl phosphate 2, yielding lipid I 3 (Scheme 1).[4]
The first X-ray crystal structure of this enzyme (from the extre-
mophile Aquifex aeolicus) was published in 2013[5a] and largely
confirmed previous in silico predictions on the transmembrane
topology of MraY.[5b] The heterologous overexpression of MraY
homologues from different bacteria has been reported, thus
enabling more detailed studies on its biochemical properties.[6]
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thereby enabling a more efficient access to structural variations,
particularly of the muraymycin peptide moiety. The efficiency
of this new method was exemplified in an alanine scan of the
peptide unit. The inhibitory in vitro activities of the resultant
analogues towards MraY provided novel SAR insights. Overall,
this new synthetic method for the preparation of muraymycin
analogues might support the development of these antibacte-
rial agents towards potential drug candidates.
Scheme 1. MraY-catalysed reaction towards lipid I 3.
A range of uridine-derived natural products (′nucleoside
antibiotics′) have been found to inhibit MraY, making them
promising candidates for drug development efforts.[7] We focus
our attention on the subclass of muraymycin nucleoside anti-
biotics.[7c] Muraymycins were first isolated in 2002 and demon-
strated activity against the growth of several bacterial strains
including S. aureus.[8] They are generally composed of a glycyl-
uridine (GlyU) core unit linked (by a propyl linker) to a peptide
moiety. One of the most active members of the subclass is
muraymycin A1 4 (Figure 1), bearing an aminoribose motif in
the GlyU 5′-position. By now, even more active congeners have
been identified.[8b]
In 2016, an X-ray co-crystal structure of MraY from Aquifex
aeolicus in complex with muraymycin D2 5 (Figure 1) as inhibi-
tor was reported.[9] This work provided deeper insights into the
binding mode of muraymycins to MraY, showing that the
uridine motif and the 5′-aminoribose unit are bound in defined
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Figure 1. Structures of selected naturally occurring muraymycins 4 and 5 and
of the bioactive synthetic 5′-defunctionalised analogue 6.
pockets while the peptide moiety mainly lies on the surface of
the protein. However, the significant conformational plasticity
of the enzyme makes it difficult to predict a potential inhibitor′s
affinity by molecular modelling. Hence, experimental investiga-
tions on the structure-activity relationship (SAR) are the most
Scheme 2. Previously reported syntheses of muraymycin analogues by Ichikawa et al. (A) and Ducho et al. (B) and novel approach of this work (C).
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promising option in order to develop muraymycins and their
analogues towards antibacterial drug candidates. Several previ-
ous SAR studies on muraymycins and their analogues have
demonstrated the relevance of specific parts of the muraymycin
scaffold,[10] but variations in the peptide unit have not been
comprehensively explored yet.
For further detailed SAR studies on muraymycins and their
analogues (e.g. derivative 6, Figure 1), an efficient synthetic ac-
cess to these nucleoside-peptide hybrid structures is of utmost
importance. Ichikawa et al. applied an Ugi four-component
reaction to furnish muraymycins, e.g. muraymycin D2 5
(Scheme 2, route A).[11] For this, they used building blocks 7–10
including uridine derivative 10. The four-component reaction
furnished a 1:1-mixture of epimers at the leucine moiety that
could be separated by HPLC. As an alternative, we have devel-
oped a stereocontrolled tripartite approach (Scheme 2, route B)
employing urea dipeptide 11, aldehyde 12 and uridine deriva-
tive 13 as suitably protected building blocks.[10f ] To reduce syn-
thetic effort, we have mainly focussed on 5′-defunctionalised
(′5′-deoxy′) analogues[12] as some of these compounds (e.g. de-
rivative 6, Figure 1) were found to exhibit inhibitory activity
towards MraY in the nanomolar range, in spite of the structural
simplification.[10h] This justifies the use of these synthetically
less challenging analogues for SAR studies.
As part of our ongoing studies on nucleoside antibiotics, we
currently examine variations in the muraymycin peptide unit.
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One goal is to elucidate which amino acids are essential for
MraY inhibition and to what extent they contribute to the in-
hibitory activity. Thus, we now report an alanine scan of the
peptide moiety, i.e. a one-by-one replacement of its three L-
amino acids with L-alanine and subsequent biological evalua-
tion of the resultant muraymycin analogues. To facilitate the
synthesis, we have developed an alternative approach
(Scheme 2, route C), i.e. a modular method based on solid
phase-supported peptide synthesis (SPPS).
Results and Discussion
Solid phase-supported approaches have been reported before
for the mureidomycin/sansanmycin subclasses of uridine-
derived nucleoside antibiotics, which are structurally related to
muraymycins.[13] In their solid phase-supported synthesis of
sansanmycins, Tran et al. have established the strategy to form
the sansanmycin peptide unit on the solid phase and couple it
to the nucleoside building block in solution at a later stage.[13b]
For our novel approach towards muraymycins, we have similarly
combined the solid phase-supported synthesis of the urea-con-
taining peptide moiety 14 (via 15) with late-stage connection
to the nucleoside building block 13 (Scheme 2, route C). We
have envisioned that this would enable rapid access to varia-
tions in the peptide unit. Furthermore, reactions involving the
nucleoside building block 13 are reduced to a minimum be-
cause of its modular introduction in the penultimate step of the
synthesis (prior to global deprotection). The 5′-defunctionalised
variation 13 of the muraymycin nucleoside unit was chosen for
the aforementioned reasons (vide supra).
It is known from literature precedent that a final global de-
protection step under acidic conditions furnishes muraymycins
and their analogues in a reliable and robust manner.[10,11]
Hence, the overall strategy for the protection of amino acid
side chains and the cleavage of the peptide unit from the solid
support was conceived accordingly. For the envisioned solid
phase-supported synthesis, we have chosen a trityl resin in
combination with an Fmoc protecting group strategy. As Fmoc
is a standard protecting group used in SPPS, well-established
protocols are available.[14] The trityl resin is cleavable under
mild acidic conditions and can thus be orthogonally used in
combination with acid-sensitive side chain protecting groups
such as Boc (which requires harsher conditions for cleavage). In
contrast to standard SPPS, we intended to prepare a peptide-
linker aldehyde 14 that would undergo reductive amination
after its cleavage from the resin. Konno et al. reported the prep-
aration of similar peptides on solid support,[15] but obtained
epimers for the amino acid bearing the aldehyde functionality.
However, this problem was impossible for our synthetic route
because of the propyl linker between the first amino acid and
the aldehyde functionality.
For appropriate functionalisation of the resin, we first con-
verted 1-amino-3,3-diethoxypropane 16 into Fmoc-protected
aldehyde 17 (Scheme 3). Thus, Fmoc protection and acidic
cleavage of the acetal furnished 17 in 64 % yield over two steps.
Aldehyde 17 was further transformed into 1,3-dioxolane 18 by
acetalisation with 1,2,6-hexanetriol in 89 % yield. Subsequent
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metal-free oxidation of the primary alcohol 18 under TEMPO-
Pinnick conditions afforded carboxylic acid 19 in 75 % yield.
Acid 19 would later serve as a linker unit for the attachment to
the trityl resin by tritylation of the carboxylate.
Scheme 3. Synthesis of the linker unit 19 and of building blocks 21a,b for
urea formation.
For the formation of the urea peptide motif on the solid
support, p-nitrophenyl carbamates of the terminal amino acids
were prepared as building blocks (Scheme 3). Thus, L-valine tert-
butyl ester 20a (R = iPr) and L-alanine tert-butyl ester 20b (R =
Me), respectively, were treated with p-nitrophenyl chloroform-
ate. This directly furnished the desired p-nitrophenyl carb-
amates 21a (valine derivative, R = iPr) and 21b (alanine deriva-
tive, R = Me) in yields of 53 % and 57 %, respectively.
The solid phase-supported reaction sequence started with
the attachment of the carboxylic acid 19 to the 2-chlorotrityl
chloride resin, furnishing resin-bound, Fmoc-protected interme-
diate 22 (Scheme 4). Non-converted trityl groups on the resin
were capped with a mixture of CH2Cl2, MeOH and DIPEA. For
subsequent Fmoc deprotection, 20 % piperidine in DMF was
added to the resin and the mixture was shaken thoroughly (2 ×
10 min). Coupling of the first amino acid AA1 was performed
using an excess of 3.0 equivalents (eq) of the Fmoc- and side
chain-protected amino acid, 3.0 eq of HBTU as coupling reagent
and 6 eq of DIPEA in DMF, thus yielding resin-linked amino acid
23. All coupling steps were performed twice. Reaction times
between 2 and 40 h were tolerated, but at least one of the
coupling steps was left for 12 h or longer to complete. Washing
steps with DMF and CH2Cl2 were carried out after each depro-
tection and coupling step.
The next amino acid AA2 was coupled using the same proto-
col (Scheme 4). After cleavage of the Fmoc group, resin-linked
dipeptide 24 was furnished, which then underwent urea forma-
tion by treatment with p-nitrophenyl carbamate 21a or 21b in
the presence of DIPEA in DMF. The resultant urea peptide 25
was then cleaved from the resin using 1,1,1,3,3,3-hexafluoro-2-
Full Paper
Scheme 4. SPPS of the muraymycin peptide unit and subsequent reactions towards muraymycin analogues 28a–d. Steps: A: all resin-bound SPPS steps;
B: transacetalisation; C: aldehyde formation; D: reductive amination and global deprotection. Yields for steps A–D are provided in Table 1.
propanol (HFIP), which left the acidically cleavable Boc protect-
ing group and the tert-butyl ester intact. This afforded 1,3-diox-
olane 26 as a stereoisomeric mixture at the dioxolane unit,
which was treated with ethanethiol and boron trifluoride to
give dithioacetal 27. This transformation usually proceeded
with good yields (67–85 %, vide infra), even though sometimes
the formation of partially deprotected side products occurred
and extended reaction periods of several days were necessary.
The thus obtained dithioacetal 27 was cleaved with N-
bromosuccinimide and 2,6-lutidine[16] to regain the aldehyde
functionality in peptides of type 14 (Scheme 4, also cf.
Scheme 2). The resultant aldehyde was then used for reductive
amination with the nucleoside building block 13[12b] (cf.
Scheme 2) using sodium borohydride and amberlyst as acidic
activator. After global deprotection with aqueous trifluoroacetic
acid and HPLC purification, the desired muraymycin analogues
28a–d were obtained as TFA salts. The yields over the final two
steps ranged from 39 to 58 % (vide infra). Considering that re-
ductive aminations of similar systems have sometimes been
problematic with respect to robustness and the occurrence of
side products, these yields can be considered satisfying.
Target compound 28d represents a previously reported sim-
plified muraymycin analogue[10i] containing the 5′-defunction-
alised version of the nucleoside core unit and the amino acid
sequence valine-lysine-leucine (all-L) in the peptide moiety.
Thus, it is an analogue of D-series muraymycins with lysine re-
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placing the synthetically challenging epicapreomycidine unit.
All other target compounds 28a–c are novel and part of an
alanine scan of the muraymycin peptide unit, with 28d serving
as the reference compound. Thus, in 28a L-alanine replaces the
native L-leucine, while in 28b the L-lysine and in 28c the L-valine
motifs, respectively, are replaced by L-alanine.
Yields for the SPPS-based synthesis of 28a–d are listed in
Table 1 (also cf. Scheme 4). For step(s) A (combination of all
resin-bound SPPS steps), they were in the range of 48–73 %
and for step B (transacetalisation) in the range 67–85 % (vide
supra). Step C (aldehyde formation) proceeded with 37–63 %
yield and step D (reductive connection to the nucleoside and
deprotection) with 39–52 % yield (including preparative HPLC
purification of the target compounds, vide supra). Thus, overall
yields were in the range of 9–14 %, demonstrating the effi-
Table 1. Yields [%] for synthetic steps A–D depicted in Scheme 4.
Compound[a] A B C D overall[b]
28a (Val-Lys-Ala) 67 72 55 39 10
28b (Val-Ala-Leu) 53 85 54 58 14
28c (Ala-Lys-Leu) 48 74 63 46 10
28d (Val-Lys-Leu) 73 67 37 52 9
[a] In parentheses: amino acid sequence in order R3-R2-R1 (see Scheme 4),
with positions of alanine replacements (relative to 28d) highlighted in bold.
[b] Overall yields from precursor 19.
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ciency of the novel SPPS-based route with respect to the signifi-
cant number of transformations and the facileness of purifica-
tion.
The novel target compounds 28a–c were investigated for
their inhibitory potency towards the bacterial target protein
MraY, using an established fluorescence-based in vitro assay for
MraY activity.[17] For this assay, a crude membrane preparation
of MraY from S. aureus (heterologously overexpressed in E. coli)
was employed as described before.[10f,10h,10i,10j,17] The results
thus obtained, including the previously reported inhibitory po-
tency of reference compound 28d,[10i] are given in Table 2.
Table 2. In vitro inhibitory potencies (IC50 values in μM)[a] of muraymycin
analogues 28a–d towards the bacterial target protein MraY.
28a 28b 28c 28d
(Val-Lys-Ala)[b] (Val-Ala-Leu)[b] (Ala-Lys-Leu)[b] (Val-Lys-Leu)[b]
95 ± 40 14 ± 2 21 ± 4 2.5 ± 0.6
[a] Mean ±SD of triplicate measurements. [b] In parentheses: amino acid se-
quence in order R3-R2-R1, with positions of alanine replacements (relative to
28d) highlighted in bold.
All novel analogues 28a–c showed some inhibitory activity
towards MraY in the μM range, even though their potencies
were lower than the activity of reference compound 28d. The
formal replacement of the central L-leucine with L-alanine (28a)
gave the most pronounced loss of inhibitory potency (ca.
40-fold) relative to 28d. In contrast, exchanging the cationic
L-lysine motif (28b) and the terminal L-valine unit (28c) with
L-alanine only reduced the inhibitory activities ca. 6-fold (for
28b) and ca. 8-fold (for 28c), respectively. Hence, the alanine
scan approach revealed that the central L-leucine residue plays
the most essential role of all three amino acid moieties in the
binding of muraymycin analogues to MraY, probably due to
hydrophobic interactions with the protein in this position.
It should be noted that these results were obtained using a
simplified (5′-deoxy) version of the muraymycin scaffold. How-
ever, the fact that such 5′-deoxy analogues can display low-μM
to nM[10h] activities as MraY inhibitors demonstrate their validity
as surrogates for naturally occurring muraymycins. This strongly
suggests that the obtained insights into the interaction of
28a–c with MraY will also be valid for the parent natural prod-
ucts. Furthermore, the results are in good agreement with the
current knowledge on MraY and its inhibition. It is known that
the protein shows pronounced conformational plasticity and
that the muraymycin peptide unit is accommodated in a rather
solvent-exposed position on the surface of the active site,
rather than in a defined pocket.[9] This is reflected in the obser-
vation that none of the three amino acid replacements with
L-alanine led to a dramatic loss of inhibitory potency towards
MraY as no key interaction seems to be mediated by any of the
three side chains. It can also be assumed that the protein can
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most likely conformationally adapt to moderate changes in the
structure of the peptide unit.
We had reported before that the simplified muraymycin
analogue 28d is not antibacterially active in cellulo (MIC >
50 μg/mL against E. coli), probably as a result of its moderately
potent target interaction in combination with limited cellular
uptake.[10i] Therefore, we have not studied novel analogues
28a–c for potential antibacterial effects in cellulo as they were
weaker MraY inhibitors than 28d. Thus, 28a–c served as tool
compounds to map MraY-ligand interactions for muraymycin-
derived MraY inhibitors rather than as candidate compounds
for muraymycin analogues with improved antibacterial activi-
ties.
Conclusions
In summary, we have successfully established a novel solid
phase-supported strategy for the synthesis of muraymycin ana-
logues. Our novel approach is modular and efficient, as demon-
strated by the facile preparation of three novel and one previ-
ously reported muraymycin analogue(s) for an alanine scan of
the muraymycin peptide unit. In vitro studies on the inhibitory
activities of these compounds 28a–d towards the bacterial tar-
get protein MraY revealed that all alanine-containing analogues
were still reasonably potent MraY inhibitors. However, MraY in-
hibition was most hampered when the central L-leucine motif
of the muraymycin scaffold was formally exchanged to
L-alanine. This indicated that the leucine unit rather strongly
contributes to the interaction with MraY, most likely due to
hydrophobic contacts.
Our results are useful to guide the future design of muray-
mycin analogues. Firstly, they suggest that the central L-leucine
or (O-acylated) 3-hydroxy-L-leucine motif, respectively, should
either be retained or only be incrementally altered. Secondly, it
is obvious that the valine and lysine units may be exchanged
into different amino acids. This might be useful in the design
of muraymycin conjugates or tagged muraymycin analogues as
probes to further study the cellular interactions of this class of
compounds. The SPPS strategy should also enable the introduc-
tion of amino acids with accordingly functionalised side chains,
even though this might require the adjustment of some reac-
tion conditions.
Overall, the reported efficient SPPS-based methodology for
the synthesis of muraymycin analogues will thereby enable fur-
ther variations in the muraymycin peptide unit. With respect to
the modular nature of this novel synthetic strategy, variations
in the nucleoside moiety will also be feasible. This will facilitate
more detailed SAR studies on this promising class of antibacte-
rial agents, and work along this line is currently on the way in
our laboratories.
Experimental Section
General Methods: Chemicals were purchased from standard sup-
pliers and used without further purification. Reactions involving
oxygen- and/or moisture-sensitive reagents were carried out under
an atmosphere of nitrogen using anhydrous solvents. The glass
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equipment used for these reactions was dried by heating prior to
use. Anhydrous solvents were obtained in the following manner:
CH2Cl2, THF and DMF were purchased in HPLC quality and dried
with a solvent purification system (MBRAUN MB SPS 800). MeOH
was of absolute quality, degassed and stored over activated molec-
ular sieves (3 Å). NEt3 was of absolute quality, degassed and stored
over activated molecular sieves (4 Å). Solvents for reactions without
inert conditions, extractions, and chromatography were of technical
quality and distilled prior to their use. All other solvents were of
p.a. quality, and distilled water was used throughout. Column chro-
matography was carried out on silica gel 60 (0.040–0.063 mm, 230–
400 mesh ASTM, VWR) under flash conditions. TLC was performed
on aluminium plates precoated with silica gel 60 F254 (VWR). Visuali-
sation of the spots was carried out using UV light (254 nm) where
appropriate and/or staining under heating [KMnO4 staining solu-
tion: 1 g of KMnO4, 6 g of K2CO3 and 1.5 mL of 5 % NaOHaq (w/v),
all dissolved in 100 mL of H2O; ninhydrin staining solution: 0.3 g of
ninhydrin, 3 mL of AcOH, all dissolved in 100 mL of 1-butanol,
H2SO4 staining solution: 4 g of vanillin, 25 mL of conc. H2SO4, 80 mL
of AcOH, all dissolved in 680 mL of MeOH]. Semipreparative HPLC
was performed on an Agilent Technologies 1200 Series system
equipped with an MWD detector (254.16/280.16) and a LiChro-
CartTM column (10 × 250 mm) containing reversed phase silica gel
PurospherTM RP18e (5 μm, VWR). Method 1: eluent A water (+0.1 %
TFA), eluent B MeCN (+0.1 % TFA); 0–25 min gradient of B (3–30 %),
25–30 min gradient of B (30–100 %), 30–35 min 100 % B, 35–36 min
gradient of B (100–3 %); flow 3 mL/min. Method 2: eluent A water
(+0.1 % TFA), eluent B MeCN (+0.1 % TFA); 0–25 min gradient of B
(2–20 %), 25–30 min gradient of B (20–100 %), 30–35 min 100 % B,
35–36 min gradient of B (100–2 %); flow 3 mL/min. 500 MHz-1H
NMR, 126 MHz-13C NMR and 376 MHz-19F NMR spectra were re-
corded on Bruker AVANCE-500 spectrometers. All 13C NMR spectra
are 1H-decoupled. All spectra were recorded at room temperature
and were referenced internally to solvent reference frequencies.
Chemical shifts (δ) are quoted in ppm. Coupling constants (J) are
reported in Hz to the nearest 0.1 Hz. The assignment of signals was
carried out using 1H,1H-COSY, HSQC and HMBC spectra obtained
on the spectrometers mentioned above. High resolution (HR) ESI
mass spectrometry was carried out on a Dionex UltiMate 3000 HPLC
system and on a Bruker time-of-flight (TOF) maXis. Infrared spectro-
scopy (IR) was performed on a Bruker Vertex 70 spectrometer
equipped with an integrated ATR unit (PlatinumATRTM). Wavenum-
bers (ν̃) are quoted in cm–1. UV spectroscopy was carried out on
an Agilent Cary 100 spectrophotometer. Wavelengths of maximum
absorption (λmax) are reported in nm.
General Procedure (GP1) for the synthesis of p-nitrophenyl
carbamates: The respective amino acid tert-butyl ester 20
(1.0 equiv.) was dissolved in CH2Cl2, and DIPEA (1.0 equiv.) and p-
nitrophenyl chloroformate (1.2 equiv.) were added. The mixture was
stirred at r.t. overnight. The solvent was evaporated under reduced
pressure and the resultant crude product was purified by column
chromatography to give the respective p-nitrophenyl carbamate 21.
General Procedure (GP2) for solid phase-supported peptide
synthesis: 2-Chlorotrityl chloride resin (1.0–1.3 equiv.) was weighed
into a syringe equipped with a filter frit, pre-dried and allowed to
swell in CH2Cl2 for 30–60 min. N-Fmoc-protected carboxylic acid 19
(1.0 equiv.) and DIPEA (3.0 equiv.) were dissolved in CH2Cl2 and
added to the resin, and the mixture was shaken at r.t. for several
hours. The solution was then filtered off, the resin was washed with
DMF, CH2Cl2 and DMF again (5 × 2–4 mL each). A solution of CH2Cl2,
MeOH and DIPEA (17:2:1) was added to the resin, and the mixture
was shaken for 5 min to cap remaining trityl chloride moieties. The
resin was then washed again with DMF, CH2Cl2 and DMF. Fmoc
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deprotection was carried out by shaking the resin with a solution
of 20 % piperidine in DMF for 10 min. It was then washed with
DMF, CH2Cl2 and DMF (5 × 2–4 mL each). The procedure was carried
out twice. The N-Fmoc-protected amino acid AA1 (6 equiv.), HBTU
(6 equiv.) and DIPEA (12 equiv.) were dissolved in DMF under inert
gas conditions. The solution was added to the resin in two portions,
and the mixture was shaken at r.t. for 1–4 h for the first coupling
and 16–40 h for the second. The resin was then washed with DMF,
CH2Cl2 and DMF (5 × 2–4 mL each). Fmoc deprotection and cou-
pling with the second amino acid AA2 were carried out in the same
manner. For urea formation, the p-nitrophenyl carbamate of the
respective amino acid (2.0 equiv.) and DIPEA (4.0 equiv.) were dis-
solved in DMF. The solution was added to the resin, and the mixture
was shaken at r.t. for 6 h and then washed with DMF and CH2Cl2
(5 × 2–4 mL each).
General Procedure (GP3) for cleavage from the resin: A solution
of 20 % HFIP in CH2Cl2 was added to the resin, and the mixture was
shaken at r.t. for 1 h. The resin was then washed 10–15 times with
CH2Cl2 (2–4 mL each). The combined solutions were evaporated
under reduced pressure to give the respective carboxylic acid 26.
General Procedure (GP4) for dithioacetal formation: The respec-
tive 1,3-dioxolane 26 (1.0 equiv.) was dissolved in CH2Cl2 and boron
trifluoride diethyl etherate (0.10–0.15 equiv.) and ethanethiol (15–
20 equiv.) were added. The mixture was stirred at r.t. for several
days and boron trifluoride diethyl etherate was added if necessary.
When the reaction was complete, DIPEA (6.0 equiv.) was added, and
the reaction mixture was washed with water (2 ×) and brine (2 ×).
The organic layer was dried with Na2SO4, the solvent was evapo-
rated under reduced pressure and the resultant crude product was
purified by column chromatography to give the respective dithio-
acetal 27.
General Procedure (GP5) for thioacetal cleavage: The respective
dithioacetal 27 (1.0 equiv.) was dissolved in a mixture of MeCN,
water and acetone (8:2:1). At 0 °C, NBS (8 equiv.) and 2,6-lutidine
(16 equiv.) were added, the reaction mixture was stirred for 5–
10 min, and the reaction was then quenched with sat. Na2S2O3
solution (10–20 mL). The aqueous layer was extracted with CH2Cl2
(3 ×), and the combined organics were washed with brine (1 ×) and
dried with Na2SO4. The solvent was evaporated under reduced pres-
sure and the resultant crude product was purified by column chro-
matography.
General Procedure (GP6) for reductive amination: The respective
peptide aldehyde 14 (1.0 equiv.) was dissolved in THF over molec-
ular sieves (4 Å), nucleoside 13[12b] (1.2 equiv.) was added and the
mixture was stirred at r.t. for 1 d. Then, amberlyst-15TM (spatula tip)
and sodium triacetoxyborohydride (2.0 equiv.) were added and the
mixture was stirred at r.t. overnight. The reaction mixture was
filtered and the insoluble material was washed with EtOAc. The
combined filtrates were washed with sat. Na2CO3 solution (1 ×), and
the aqueous layer was extracted with EtOAc (1 ×). The combined
organics were dried with Na2SO4, the solvent was evaporated under
reduced pressure and the resultant crude product was purified by
column chromatography to give the respective fully protected
muraymycin analogue.
Val-Lys-Ala peptide aldehyde (14a): General procedure GP5 with
Val-Lys-Ala peptide dithioacetal 27a (8.3 mg, 12 μmol), NBS (19 mg,
0.11 mmol) and 2,6-lutidine (23 μL, 21 mg, 0.20 mmol) in MeCN,
water and acetone (2.2 mL) over 5 min. Column chromatography
(CH2Cl2/MeOH, 99:1 → 98:2 → 95:5) gave 14a as a colourless solid
(3.8 mg, 55 %). 1H NMR (500 MHz, CDCl3): δ = 0.86 (d, J = 6.9 Hz,
3H, Val-4-H), 0.92 (d, J = 6.9 Hz, 3H, Val-4-H), 1.27–1.50 (m, 4H, Lys-
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4-H, Lys-5-H), 1.34 (d, J = 7.2 Hz, 3H, Ala-3-H), 1.45 (s, 9H, Boc-
OC(CH3)3), 1.47 (s, 9H, OC(CH3)3), 1.75–1.81 (m, 2H, Lys-3-H), 2.08–
2.14 (m, 1H, Val-2-H), 2.70 (dt, J = 6.3, 1.1 Hz, 2H, 2-H), 3.06–3.13
(m, 2H, Lys-6-H), 3.48–3.60 (m, 2H, 3-H), 4.18–4.21 (m, 1H, Lys-2-H),
4.29–4.31 (m, 1H, Val-2-H), 4.43–4.49 (m, 1H, Ala-2-H), 4.99 (s, 1H,
Boc-NH), 5.72 (d, J = 8.2 Hz, 1H, Val-NH), 6.20 (s, 1H, Lys-NH), 6.87
(d, J = 6.1 Hz, 1H, Ala-NH), 7.38 (s, 1H, 3-NH), 9.77 (t, J = 1.1 Hz, 1H,
1-H) ppm. 13C NMR (126 MHz, CDCl3): δ = 17.67 (Ala-C-3), 18.10
(Val-C-4), 19.20 (Lys-C-4), 28.22 [OC(CH3)3], 28.65 (Boc-OC(CH3)3),
29.84 (Lys-C-5), 31.69 (Lys-C-3), 33.34 (C-3), 39.62 (Lys-C-6), 43.69
(C-2), 49.19 (Ala-C-2), 54.74 (Lys-C-2), 58.44 (Val-C-2), 79.10 (Boc-
OC(CH3)3), 82.02 [OC(CH3)3], 156.88 (Boc-C=O), 158.50 (urea-C=O),
172.31–173.12 (Ala-C-1, Lys-C-1, Val-C-1), 201.36 (C-1) ppm. HRMS
(ESI): calcd. for C27H50N5O8 [M + H]+ 572.3654, found 572.3657. IR
(ATR): ν̃ = 2970, 1737, 1626, 1541, 1366, 1229, 1217, 1157 cm–1.
UV (CHCl3): λmax = 222 nm. TLC (CH2Cl2/MeOH, 9:1): Rf = 0.33.
Val-Ala-Leu peptide aldehyde (14b): General procedure GP5 with
Val-Ala-Leu peptide dithioacetal 27b (20.6 mg, 36.6 μmol), NBS
(52.5 mg, 0.295 mmol) and 2,6-lutidine (70 μL, 64 mg, 0.60 mmol)
in MeCN, water and acetone (4.4 mL) over 7 min. Column chroma-
tography (CH2Cl2/MeOH, 99:1 → 98:2 → 95:5) gave 14b as a colour-
less solid (9.0 mg, 54 %). 1H NMR (500 MHz, CDCl3): δ = 0.86–0.92
(m, 12H, Val-4-H, Leu-5-H), 1.29 (d, J = 7.0 Hz, 3H, Ala-3-H), 1.46 (s,
9H, OC(CH3)3), 1.51–1.69 (m, 3H, Leu-3-H, Leu-4-H), 2.03–2.09 (m,
1H, Val-3-H), 2.70–2.72 (m, 2H, 2-H), 3.48–3.55 (m, 1H, 3-Ha), 3.57–
3.63 (m, 1H, 3-Hb), 4.28 (dd, J = 8.8, 4.9 Hz, 1H, Val-2-H), 4.51–4.56
(m, 1H, Leu-2-H), 4.56–4.61 (m, 1H, Ala-2-H), 6.13 (d, J = 8.8 Hz, 1H,
Val-NH), 6.44 (s, 1H, Ala-NH), 7.53 (s, 1H, Leu-NH), 7.89 (s, 1H, 3-NH),
9.76 (s, 1H, 1-H) ppm. 13C NMR (126 MHz, CDCl3): δ = 17.91 (Val-C-
4), 19.13 (Val-C-4), 19.73 (Ala-C-3), 22.43 (Leu-C-5), 22.80 (Leu-C-5),
24.93 (Leu-C-4), 28.24 [OC(CH3)3], 31.94 (Val-C-3), 33.38 (C-3), 41.34
(Leu-C-3), 43.77 (C-2), 49.51 (Ala-C-2), 52.03 (Leu-C-2), 58.47 (Val-C-
2), 81.81 [OC(CH3)3], 157.88 (urea-C=O), 172.69 (Val-C-1), 172.85
(Leu-C-1), 174.11 (Ala-C-1), 201.15 (C-1) ppm. HRMS (ESI): calcd. for
C22H41N4O6 [M + H]+ 457.3021, found 457.3021. IR (ATR): ν̃ = 3279,
2969, 1734, 1629, 1542, 1368, 1217, 1148 cm–1. UV (CHCl3): λmax =
223 nm. TLC (CH2Cl2/MeOH, 9:1): Rf = 0.27.
Ala-Lys-Leu peptide aldehyde (14c): General procedure GP5 with
Ala-Lys-Leu peptide dithioacetal 27c (18.4 mg, 26.6 μmol), NBS
(38.8 mg, 0.218 mmol) and 2,6-lutidine (50 μL, 46 mg, 0.43 mmol)
in MeCN, water and acetone (3.3 mL) over 5 min. Column chroma-
tography (CH2Cl2/MeOH, 99:1 → 98:2 → 95:5) gave 14c as a colour-
less solid (9.8 mg, 63 %). 1H NMR (500 MHz, CDCl3): δ = 0.88 (d, J =
6.6 Hz, 3H, Leu-5-H), 0.91 (d, J = 6.6 Hz, 3H, Leu-5-H), 1.32–1.37 (m,
2H, Lys-4-H), 1.33 (d, J = 7.2 Hz, 3H, Ala-3-H), 1.44 (s, 9H, Boc-
OC(CH3)3), 1.46 (s, 9H, OC(CH3)3), 1.46–1.77 (m, 7H, Leu-3-H, Leu-4-
H, Lys-3-H, Lys-5-H), 2.69 (t, J = 6.4 Hz, 2H, 2-H), 3.03–3.13 (m, 2H,
Lys-6-H), 3.51–3.57 (m, 2H, 3-H), 4.28–4.33 (m, 1H, Lys-2-H), 4.31–
4.37 (m, 1H, Ala-2-H), 4.47–4.52 (m, 1H, Leu-2-H), 5.02 (s, 1H, Boc-
NH), 5.92 (s, 1H, Ala-NH), 6.41 (s, 1H, Lys-NH), 7.02 (s, 1H, Leu-NH),
7.65 (s, 1H, 3-NH), 9.76 (s, 1H, 1-H) ppm. 13C NMR (126 MHz, CDCl3):
δ = 19.33 (Ala-C-3), 22.03 (Leu-C-5), 22.29 (Lys-C-4), 23.03 (Leu-C-5),
25.03 (Leu-C-4), 28.14 [OC(CH3)3], 28.63 (Boc-OC(CH3)3), 29.78 (Lys-
C-5), 32.12 (Lys-C-3), 33.40 (C-3), 39.67 (Lys-C-6), 40.81 (Leu-C-3),
43.66 (C-2), 49.53 (Ala-C-2), 51.94 (Leu-C-2), 54.38 (Lys-C-2), 79.39
(Boc-OC(CH3)3), 81.83 [OC(CH3)3], 156.80 (Boc-C=O), 157.99 (urea-
C=O), 172.67 (Leu-C-1), 173.27 (Lys-C-1), 173.48 (Ala-C-1), 201.35 (C-
1) ppm. HRMS (ESI): calcd. for C28H52N5O8 [M + H]+ 586.3810, found
586.3816. IR (ATR): ν̃ = 3275, 2970, 2934, 1737, 1628, 1541, 1366,
1229, 1217, 1158 cm–1. UV (CHCl3): λmax = 222 nm. TLC (CH2Cl2/
MeOH, 9:1): Rf = 0.21.
Val-Lys-Leu peptide aldehyde (14d): General procedure GP5 with
Val-Lys-Leu peptide dithioacetal 27d (26.9 mg, 37.4 μmol), NBS
Eur. J. Org. Chem. 2019, 7420–7431 www.eurjoc.org © 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim7426
(53.2 mg, 0.299 mmol) and 2,6-lutidine (70 μL, 64 mg, 0.60 mmol)
in MeCN, water and acetone (4.4 mL) over 6 min. Column chroma-
tography (CH2Cl2/MeOH, 99:1 → 98:2 → 95:5) gave 14d as a colour-
less solid (8.5 mg, 37 %). 1H NMR (500 MHz, CDCl3): δ = 0.85–0.91
(m, 12H, Val-4-H, Leu-5-H), 1.31–1.37 (m, 2H, Lys-4-H), 1.44 (s, 9H,
Boc-OC(CH3)3), 1.47 (s, 9H, OC(CH3)3), 1.46–1.77 (m, 7H, Leu-3-H,
Leu-4-H, Lys-3-H, Lys-5-H), 2.06–2.12 (m, 1H, Val-3-H), 2.68 (t, J =
6.4 Hz, 2H, 2-H), 3.01–3.15 (m, 2H, Lys-6-H), 3.47–3.59 (m, 2H, 3-H),
4.27–4.31 (m, 2H, Val-2-H, Lys-2-H), 4.39–4.44 (m, 1H, Leu-2-H), 5.05
(s, 1H, Boc-NH), 5.86 (d, J = 6.8 Hz, 1H, Val-NH), 6.32 (s, 1H, Lys-NH),
6.86 (s, 1H, Leu-NH), 7.57 (s, 1H, 3-NH), 9.75 (s, 1H, 1-H) ppm. 13C
NMR (126 MHz, CDCl3): δ = 17.76 (Val-C-4), 19.16 (Val-C-4), 22.04
(Leu-C-5), 22.24 (Lys-C-4), 22.99 (Leu-C-5), 25.01 (Leu-C-4), 28.23
[OC(CH3)3], 28.63 (Boc-OC(CH3)3), 29.79 (Lys-C-5), 31.81 (Val-C-3),
31.96 (Lys-C-3), 33.39 (C-3), 39.67 (Lys-C-6), 40.77 (Leu-C-3), 43.71
(C-2), 52.19 (Leu-C-2), 54.36 (Lys-C-2), 58.41 (Val-C-2), 79.34 (Boc-
OC(CH3)3), 81.99 [OC(CH3)3], 156.77 (Boc-C=O), 158.45 (urea-C=O),
172.53 (Lys-C-1), 172.59 (Leu-C-1), 173.42 (Val-C-1), 201.27 (C-1)
ppm. HRMS (ESI): calcd. for C30H56N5O8 [M + H]+ 614.4123, found
614.4127. IR (ATR): ν̃ = 1970, 1737, 1628, 1542, 1437, 1229, 1217,
1093 cm–1. UV (CHCl3): λmax = 223 nm. TLC (CH2Cl2/MeOH, 9:1):
Rf = 0.34.
N-Fmoc-3-aminopropanal (17): A solution of 1-amino-3,3-dieth-
oxypropane 16 (1.0 mL, 0.91 g, 6.2 mmol) and NEt3 (1.7 mL, 1.3 g,
12 mmol) in CH2Cl2 (13 mL) was cooled to 0 °C. Fmoc-chloride
(3.19 g, 12.4 mmol) was added and the mixture was stirred at r.t.
for 7 d. The solution was then washed with NH4Cl solution (2 ×
50 mL), NaHCO3 solution (50 mL) and brine (50 mL), dried with
Na2SO4 and the solvent was evaporated under reduced pressure.
The resultant crude product was purified by column chromatogra-
phy (petroleum ether/EtOAc, 8:2 → 7:3) to give a mixture of N-
Fmoc-1-amino-3,3-diethoxypropane and aldehyde 17 (2.18 g,
100 % yield: 2.28 g). This mixture was dissolved in THF (30 mL) and
HCl (1 M, 6.0 mL, 5.9 mmol) was added. The mixture was stirred at
r.t. for 5 h. Sat. NaHCO3 solution (200 mL) was then added, the
aqueous layer was extracted with EtOAc (3 × 150 mL) and the or-
ganic layer was dried with Na2SO4. The solvent was evaporated
under reduced pressure and the resultant crude product was puri-
fied by column chromatography (petroleum ether/EtOAc, 9:1 → 5:1
→ 4:1 → 1:1) to give 17 as a colourless solid (1.17 g, 64 % over 2
steps). 1H NMR (500 MHz, CDCl3): δ = 2.74 (t, J = 5.8 Hz, 2H, 2-H),
3.49 (dt, J = 5.8, 5.8 Hz, 2H, 3-H), 4.20 (t, J = 7.0 Hz, 1H, Fmoc-9-H),
4.39 (d, J = 7.0 Hz, 2H, Fmoc-CH2), 5.18 (s, 1H, 3-NH), 7.31 (t, J =
7.5 Hz, 2H, Fmoc-3-H, Fmoc-6-H), 7.40 (t, J = 7.5 Hz, 2H, Fmoc-2-H,
Fmoc-7-H), 7.57 (d, J = 7.5 Hz, 2H, Fmoc-4-H, Fmoc-5-H), 7.76 (d, J =
7.5 Hz, 2H, Fmoc-1-H, Fmoc-8-H), 9.81 (s, 1H, 1-H) ppm. 13C NMR
(126 MHz, CDCl3): δ = 34.56 (C-3), 44.17 (C-2), 47.34 (Fmoc-C-9),
66.82 (Fmoc-CH2), 120.12 (Fmoc-C-1, Fmoc-C-8), 125.15 (Fmoc-C-4,
Fmoc-C-5), 127.16 (Fmoc-C-3, Fmoc-C-6), 127.83 (Fmoc-C-2, Fmoc-
C-7), 141.44 (Fmoc-C-1a, Fmoc-C-8a), 143.99 (Fmoc-C-4a, Fmoc-C-
5a), 156.45 (Fmoc-C=O), 201.40 (C-1) ppm. HRMS (ESI): calcd. for
C18H18NO3 [M + H]+ 296.1281, found 296.1277. IR (ATR): ν̃ = 3321,
2946, 1687, 1536, 1446, 1258, 1145, 732 cm–1. UV (CHCl3):
λmax = 267, 290, 301 nm. TLC (petroleum ether/EtOAc, 1:1): Rf =
0.25.
1,3-Dioxolane (18): A solution of 1,2,6-hexanetriol (316 mg,
2.36 mmol), N-Fmoc-3-aminopropanal 17 (327 mg, 1.11 mmol) and
boron trifluoride diethyl etherate (14 μL, 16 mg, 0.11 mmol) in 1,4-
dioxane (18 mL) was stirred at r.t. for 20 h. DIPEA (0.29 mL, 0.22 g,
1.7 mmol) and EtOAc (100 mL) were then added. The organic layer
was washed with water (2 × 100 mL) and brine (2 × 100 mL), dried
with Na2SO4 and the solvent was evaporated under reduced pres-
sure. The resultant crude product was purified by column chroma-
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tography (petroleum ether/EtOAc, 1:1) to give 18 as a colourless
solid as a mixture of two diastereomers (d.r. 7:3, 409 mg, 89 %). 1H
NMR (500 MHz, CDCl3): δ = 1.39–1.71 (m, 2 × 6H, 3′-H, 4′-H, 5′-H),
1.88–1.94 (m, 2 × 2H, 2-H), 3.36–3.40 (m, 2 × 2H, 3-H), 3.46 (t, J =
7.5 Hz, 1H, 1′-Ha), 3.53 (t, J = 7.1 Hz, 1H, 1′-Ha), 3.63–3.67 (m, 2 ×
2H, 6′-H), 3.95 (t, J = 7.1 Hz, 1H, 1′-Hb), 4.03–4.11 (m, 2 × 1H, 2′-H),
4.13–4.17 (m, 1H, 1′-Hb), 4.21–4.24 (m, 2 × 1H, Fmoc-9-H), 4.37 (d,
J = 7.1 Hz, 2 × 2H, Fmoc-CH2), 4.98–5.00 (m, 1H, 1-H), 5.05–5.07 (m,
1H, 1-H), 5.29–5.32 (m, 2 × 1H, 3-NH), 7.31 (t, J = 7.5 Hz, 2 × 2H,
Fmoc-3-H, Fmoc-6-H), 7.40 (t, J = 7.5 Hz, 2 × 2H, Fmoc-2-H, Fmoc-
7-H), 7.60 (d, J = 7.5 Hz, 2 × 2H, Fmoc-4-H, Fmoc-5-H), 7.76 (d, J =
7.5 Hz, 2 × 2H, Fmoc-1-H, Fmoc-8-H) ppm. 13C NMR (126 MHz,
CDCl3): δ = 22.17, 22.23 (C-4′), 32.59–33.59 (C-2, C-3′, C-5′), 36.39
(C-3), 47.43 (Fmoc-C-9), 62.70, 62.75 (C-6′), 66.76 (Fmoc-CH2), 69.82,
70.69 (C-1′), 76.31 (C-2′), 102.90, 103.63 (C-1), 120.10 (Fmoc-C-1,
Fmoc-C-8), 125.23 (Fmoc-C-4, Fmoc-C-5), 127.14 (Fmoc-C-3, Fmoc-
C-6), 127.78 (Fmoc-C-2, Fmoc-C-7), 141.44 (Fmoc-C-1a, Fmoc-C-8a),
144.18 (Fmoc-C-4a, Fmoc-C-5a), 156.47 (Fmoc-C=O) ppm. HRMS
(ESI): calcd. for C24H30NO5 [M + H]+ 412.2118, found 412.2118. IR
(ATR): ν̃ = 3331, 2934, 2861, 1683, 1534, 1261, 1004, 620 cm–1. UV
(CHCl3): λmax = 267, 290, 301 nm. TLC (petroleum ether/EtOAc, 3:7):
Rf = 0.15.
1,3-Dioxolane carboxylic acid (19): 1,3-Dioxolane 18 (358 mg,
0.870 mmol) was dissolved in MeCN and phosphate buffer (5:3,
phosphate buffer 0.2 M, pH≈ 7, 16 mL). TEMPO (42.1 mg,
0.269 mmol), NaClO2 (156 mg, 1.72 mmol) and NaOCl solution (5 %
in water, 0.12 mL) were added and the reaction mixture was stirred
at 35 °C for 3 d. The mixture was then cooled to r.t. and EtOAc
(120 mL) was added. The organic layer was washed with sat.
Na2S2O3 solution (2 × 120 mL) and brine (2 × 120 mL), dried with
Na2SO4 and the solvent was evaporated under reduced pressure.
The resultant crude product was purified by column chromatogra-
phy (CH2Cl2/MeOH, 95:5) to give 19 as a colourless, wax-like oil
(279 mg, 75 %). 1H NMR (500 MHz, CDCl3): δ = 1.62–1.83 (m, 2 ×
4H, 3′-H, 4′-H), 1.85–1.92 (m, 2 × 2H, 2-H), 2.39–2.43 (m, 2 × 2H,
5′-H), 3.32–3.39 (m, 2 × 2H, 3-H), 3.43–3.55 (m, 2 × 1H, 1′-Ha), 3.94
(t, J = 7.2 Hz, 1H, 1′-Hb), 4.04–4.12 (m, 2 × 2H, 2′-H), 4.13–4.16 (m,
1H, 1′-Hb), 4.21–4.24 (m, 2 × 1H, Fmoc-9-H), 4.37–4.42 (m, 2 × 2H,
Fmoc-CH2), 4.94–4.98 (m, 1H, 1-H), 5.04–5.05 (m, 1H, 1-H), 5.29–5.30
(m, 2 × 1H, 3-NH), 7.29–7.32 (m, 2 × 2H, Fmoc-3-H, Fmoc-6-H), 7.39
(t, J = 7.5 Hz, 2 × 2H, Fmoc-2-H, Fmoc-7-H), 7.59–7.60 (m, 2 × 2H,
Fmoc-4-H, Fmoc-5-H), 7.76 (d, J = 7.5 Hz, 2 × 2H, Fmoc-1-H, Fmoc-
8-H) ppm. 13C NMR (126 MHz, CDCl3): δ = 21.10, 21.19 (C-4′), 32.84–
33.61 (C-2, C-3′, C-5′), 36.37 (C-3), 47.39 (Fmoc-C-9), 66.80 (Fmoc-
CH2), 69.73 (C-1′), 75.95, 76.44 (C-2′), 102.91, 103.68 (C-1), 120.08
(Fmoc-C-1, Fmoc-C-8), 125.21 (Fmoc-C-4, Fmoc-C-5), 127.13 (Fmoc-
C-3, Fmoc-C-6), 127.77 (Fmoc-C-2, Fmoc-C-7), 141.42 (Fmoc-C-1a,
Fmoc-C-8a), 144.16 (Fmoc-C-4a, Fmoc-C-5a), 156.54 (Fmoc-C=O),
178.22 (C-6′) ppm. HRMS (ESI): calcd. for C24H28NO6 [M + H]+
426.1911, found 426.1909. IR (ATR): ν̃ = 3338, 2942, 2874, 1684,
1532, 1258, 1138, 1005, 738 cm–1. UV (CHCl3): λmax = 267, 290,
301 nm. TLC (CH2Cl2/MeOH, 9:1): Rf = 0.47.
tert-Butyl [(4-nitrophenoxy)carbonyl]-L-valinate (21a): General
procedure GP1 with L-valine tert-butyl ester hydrochloride (489 mg,
2.33 mmol), DIPEA (0.40 mL, 0.30 g, 2.3 mmol) and p-nitrophenyl
chloroformate (568 mg, 2.82 mmol) in CH2Cl2 (10 mL). The reaction
mixture was stirred for 2 d. Column chromatography (petroleum
ether/EtOAc, 7:1) gave 21a as a colourless oil (416 mg, 53 %). 1H
NMR (500 MHz, CDCl3): δ = 0.96 (d, J = 6.9 Hz, 3H, 4-H), 1.03 (d, J =
6.9 Hz, 3H, 4-H), 1.50 (s, 9H, OC(CH3)3), 2.21–2.28 (m, 1H, 3-H), 4.24
(dd, J = 9.0, 4.3 Hz, 1H, 2-H), 5.67 (d, J = 9.0 Hz, 1H, NH), 7.33 (d,
J = 9.2 Hz, 2H, 2′-H, 6′-H), 8.24 (d, J = 9.2 Hz, 2H, 3′-H, 5′-H) ppm.
13C NMR (126 MHz, CDCl3): δ = 17.46 (C-4), 19.07 (C-4), 28.19
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[OC(CH3)3], 31.62 (C-3), 59.63 (C-2), 82.75 [OC(CH3)3], 122.09 (C-2′, C-
6′), 125.25 (C-3′, C-5′), 144.94 (C-4′), 153.18 (carbamate-C=O), 155.98
(C-1′), 170.75 (C-1) ppm. HRMS (ESI): calcd. for C16H23N2O6 [M + H]+
339.1551, found 339.1549. IR (ATR): ν̃ = 3339, 2969, 1719, 1521,
1486, 1343, 1204, 1144, 859 cm–1. UV (CHCl3): λmax = 277 nm. TLC
(petroleum ether/EtOAc, 5:1): Rf = 0.31.
tert-Butyl [(4-nitrophenoxy)carbonyl]-L-alaninate (21b): General
procedure GP1 with L-alanine tert-butyl ester hydrochloride
(114 mg, 0.630 mmol), DIPEA (0.11 mL, 81 mg, 0.63 mmol) and p-
nitrophenyl chloroformate (158 mg, 0.783 mmol) in CH2Cl2 (5 mL).
The reaction mixture was stirred for 23 h. Column chromatography
(CH2Cl2 → CH2Cl2/MeOH, 98:2) gave 21b as a colourless solid
(112 mg, 57 %). 1H NMR (500 MHz, CDCl3): δ = 1.47 (d, J = 7.1 Hz,
3H, 3-H), 1.49 (s, 9H, OC(CH3)3), 4.30 (dq, J = 7.4, 7.1 Hz, 1H, 2-H),
5.77 (s, 1H, NH), 7.32 (d, J = 8.9 Hz, 2H, 2′-H, 6′-H), 8.23 (d, J = 8.9 Hz,
2H, 3′-H, 5′-H) ppm. 13C NMR (126 MHz, CDCl3): δ = 18.87 (C-3),
28.10 [OC(CH3)3], 50.51 (C-2), 82.75 [OC(CH3)3], 122.13 (C-2′, C-6′),
125.25 (C-3′, C-5′), 144.95 (C-4′), 152.45 (carbamate-C=O), 155.91 (C-
1′), 171.76 (C-1) ppm. HRMS (ESI): calcd. for C14H19N2O6 [M + H]+
311.1238, found 311.1250. IR (ATR): ν̃ = 3307, 2941, 1735, 1700,
1526, 1371, 1217, 1148, 1002, 865 cm–1. UV (CHCl3): λmax = 276 nm.
TLC (CH2Cl2/MeOH, 95:5): Rf = 0.71.
SPPS of Val-Lys-Ala peptide unit (26a): 26a was prepared accord-
ing to general procedure GP2. Loading was carried out with carb-
oxylic acid 19 (38.0 mg, 89.3 μmol) in CH2Cl2 (3 mL), 2-chlorotrityl
chloride resin (79.1 mg, 90.2 μmol) and DIPEA (0.05 mL, 0.04 g,
0.3 mmol) over 19 h. The Fmoc group was cleaved, and N-Fmoc-L-
alanine (164 mg, 0.527 mmol) was coupled using HBTU (201 mg,
0.530 mmol) and DIPEA (0.18 mL, 0.14 g, 1.1 mmol) over 1 h and
16 h. The peptide was Fmoc-deprotected, and Nα-Fmoc-Nε-Boc-L-
lysine (251 mg, 0.536 mmol) was coupled using HBTU (219 mg,
0.577 mmol) and DIPEA (0.18 mL, 0.14 g, 1.1 mmol) over 1.5 h and
17 h. The peptide was Fmoc-deprotected, the urea unit was formed
with tert-butyl [(4-nitrophenoxy)carbonyl]-L-valinate 21a (105 mg,
0.310 mmol) and DIPEA (0.06 mL, 0.05 mg, 0.4 mmol) and the pept-
ide was cleaved from the resin according to general procedure GP3.
The resultant crude product was purified by column chromatogra-
phy (CH2Cl2/MeOH, 98:2 → 95:5 → 9:1) to give 26a (mixture of 1,3-
dioxolane diastereomers) as a colourless solid (41.7 mg, 67 %). 1H
NMR (500 MHz, CDCl3): δ = 0.87 (d, J = 6.2 Hz, 2 × 3H, Val-4-H), 0.92
(d, J = 5.8 Hz, 2 × 3H, Val-4-H), 1.35 (d, J = 6.3 Hz, 2 × 3H, Ala-3-H),
1.43 (s, 2 × 9H, Boc-OC(CH3)3), 1.46 (s, 2 × 9H, OC(CH3)3), 1.33–1.94
(m, 2 × 12H, Lys-3-H, Lys-4-H, Lys-5-H, 2-H, 3′-H, 4′-H), 2.11–2.17 (m,
2 × 1H, Val-3-H), 2.37–2.55 (m, 2 × 2H, 5′-H), 3.08–3.09 (m, 2 × 2H,
Lys-6-H), 3.35–3.41 (m, 2 × 2H, 3-H), 3.54–3.56 (m, 2 × 1H, 1′-Ha),
3.88–3.92 (m, 2 × 1H, 2′-H), 4.04–4.06 (m, 2 × 1H, 1′-Hb), 4.26–4.32
(m, 2 × 2H, Val-2-H, Lys-2-H), 4.48–4.49 (m, 2 × 1H, Ala-2-H), 4.97–
4.98 (m, 2 × 1H, 1-H) ppm. TLC (CH2Cl2/MeOH, 9:1): Rf = 0.14.
SPPS of Val-Ala-Leu peptide unit (26b): 26b was prepared ac-
cording to general procedure GP2. Loading was carried out with
carboxylic acid 19 (39.3 mg, 92.4 μmol) in CH2Cl2 (1.5 mL), 2-chloro-
trityl chloride resin (96.3 mg, 110 μmol) and DIPEA (0.05 mL, 0.04 g,
0.3 mmol) over 18 h. The Fmoc group was cleaved, and N-Fmoc-L-
leucine (196 mg, 0.555 mmol) was coupled using HBTU (210 mg,
0.554 mmol) and DIPEA (0.19 mL, 0.14 g, 1.1 mmol) over 2 h and
17 h. The peptide was Fmoc-deprotected, and N-Fmoc-L-alanine
(196 mg, 0.630 mmol) was coupled using HBTU (207 mg,
0.546 mmol) and DIPEA (0.19 mL, 0.14 g, 1.1 mmol) over 2 h and
40 h. The peptide was Fmoc-deprotected, the urea unit was formed
with tert-butyl [(4-nitrophenoxy)carbonyl]-L-valinate 21a (95.0 mg,
0.281 mmol) and DIPEA (0.06 mL, 0.05 mg, 0.4 mmol) and the pept-
ide was cleaved from the resin according to general procedure GP3.
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The resultant crude product was purified by column chromatogra-
phy (CH2Cl2/MeOH, 9:1) to give 26b (mixture of 1,3-dioxolane dia-
stereomers) as a colourless solid (28.6 mg, 53 %). 1H NMR (500 MHz,
CDCl3): δ = 0.83–0.91 (m, 2 × 12H, Val-4-H, Leu-5-H), 1.26 (d, J =
6.6 Hz, 2 × 3H, Ala-3-H), 1.46 (s, 2 × 9H, OC(CH3)3), 1.50–1.92 (m, 2 ×
9H, Leu-3-H, Leu-4-H, 2-H, 3′-H, 4′-H), 2.05–2.12 (m, 2 × 1H, Val-3-
H), 2.33–2.45 (m, 2 × 2H, 5′-H), 3.31–3.42 (m, 2 × 2H, 3-H), 3.48–3.52
(m, 2 × 1H, 1′-Ha), 3.87–3.91 (m, 2 × 1H, 2′-H), 3.99–4.11 (m, 2 × 1H,
1′-Hb), 4.30–4.33 (m, 2 × 1H, Val-2-H), 4.42–4.49 (m, 2 × 2H, Leu-2-
H, Ala-2-H), 4.93–5.00 (m, 2 × 1H, 1-H) ppm. TLC (CH2Cl2/MeOH, 9:1):
Rf = 0.16.
SPPS of Ala-Lys-Leu peptide unit (26c): 26c was prepared accord-
ing to general procedure GP2. Loading was carried out with carb-
oxylic acid 19 (39.5 mg, 92.8 μmol) in CH2Cl2 (1 mL), 2-chlorotrityl
chloride resin (86.0 mg, 98.0 μmol) and DIPEA (0.05 mL, 0.04 g,
0.3 mmol) over 19 h. The Fmoc group was cleaved, and N-Fmoc-L-
leucine (212 mg, 0.600 mmol) was coupled using HBTU (221 mg,
0.583 mmol) and DIPEA (0.20 mL, 0.15 g, 1.2 mmol) over 2 h and
40 h. The peptide was Fmoc-deprotected, and Nα-Fmoc-Nε-Boc-L-
lysine (280 mg, 0.598 mmol) was coupled using HBTU (240 mg,
0.633 mmol) and DIPEA (0.20 mL, 0.15 g, 1.2 mmol) over 2 h and
16 h. The peptide was Fmoc-deprotected, the urea unit was formed
with tert-butyl [(4-nitrophenoxy)carbonyl]-L-alaninate 21b (71.9 mg,
0.231 mmol) and DIPEA (0.07 mL, 0.05 mg, 0.4 mmol) and the pept-
ide was cleaved from the resin according to general procedure GP3.
The resultant crude product was purified by column chromatogra-
phy (CH2Cl2/MeOH, 95:5 → 9:1) to give 26c (mixture of 1,3-dioxol-
ane diastereomers) as a colourless solid (31.8 mg, 48 %). 1H NMR
(500 MHz, CDCl3): δ = 0.85 (d, J = 6.2 Hz, 2 × 3H, Leu-5-H), 0.89 (d,
J = 6.1 Hz, 2 × 3H, Leu-5-H), 1.31 (d, J = 7.2 Hz, 2 × 3H, Ala-3-H),
1.41 (s, 2 × 9H, Boc-OC(CH3)3), 1.44 (s, 2 × 9H, OC(CH3)3), 1.27–1.33
(m, 2 × 2H, Lys-4-H), 1.41–1.93 (m, 2 × 13H, Leu-3-H, Leu-4-H, Lys-
3-H, Lys-5-H, 2-H, 3′-H, 4′-H), 2.32–2.43 (m, 2 × 2H, 5′-H), 3.01–3.04
(m, 2 × 2H, Lys-6-H), 3.36–3.41 (m, 2 × 2H, 3-H), 3.47–3.52 (m, 2 ×
1H, 1′-Ha), 3.86–3.90 (m, 2 × 1H, 2′-H), 3.97–4.11 (m, 2 × 1H, 1′-Hb),
4.31–4.37 (m, 2 × 1H, Ala-2-H), 4.42–4.47 (m, 2 × 1H, Lys-2-H), 4.47–
4.53 (m, 2 × 1H, Leu-2-H), 4.92–5.01 (m, 2 × 1H, 1-H), 5.19–5.23 (m,
2 × 1H, Boc-NH), 6.18 (s, 2 × 1H, Ala-NH), 6.53 (s, 2 × 1H, Lys-NH),
7.40–7.53 (m, 2 × 1H, 3-NH), 7.64–7.68 (m, 2 × 1H, Leu-NH) ppm.
TLC (CH2Cl2/MeOH, 9:1): Rf = 0.16.
SPPS of Val-Lys-Leu peptide unit (26d): 26d was prepared accord-
ing to general procedure GP2. Loading was carried out with carb-
oxylic acid 19 (36.8 mg, 86.5 μmol) in CH2Cl2 (1.5 mL), 2-chlorotrityl
chloride resin (95.4 mg, 109 μmol) and DIPEA (0.05 mL, 0.04 g,
0.3 mmol) over 18 h. The Fmoc group was cleaved, and N-Fmoc-L-
leucine (187 mg, 0.529 mmol) was coupled using HBTU (198 mg,
0.522 mmol) and DIPEA (0.18 mL, 0.14 g, 1.1 mmol) over 2 h and
17 h. The peptide was Fmoc-deprotected, and Nα-Fmoc-Nε-Boc-L-
lysine (248 mg, 0.529 mmol) was coupled using HBTU (198 mg,
0.522 mmol) and DIPEA (0.18 mL, 0.14 mg, 1.1 mmol) over 2 h and
40 h. The peptide was Fmoc-deprotected, the urea unit was formed
with tert-butyl [(4-nitrophenoxy)carbonyl]-L-valinate 21a (70.0 mg,
0.207 mmol) and DIPEA (0.06 mL, 0.05 mg, 0.4 mmol) and the pept-
ide was cleaved from the resin according to general procedure GP3.
The resultant crude product was purified by column chromatogra-
phy (CH2Cl2/MeOH, 9:1) to give 26d (mixture of 1,3-dioxolane dia-
stereomers) as a colourless solid (46.9 mg, 73 %). 1H NMR (500 MHz,
CDCl3): δ = 0.82–0.89 (m, 2 × 12H, Val-4-H, Leu-5-H), 1.43 (s, 2 × 9H,
Boc-OC(CH3)3), 1.45 (s, 2 × 9H, OC(CH3)3), 1.25–1.90 (m, 2 × 15H,
Leu-3-H, Leu-4-H, Lys-3-H, Lys-4-H, Lys-5-H, 2-H, 3′-H, 4′-H), 2.07–
2.10 (m, 2 × 1H, Val-3-H), 2.33–2.42 (m, 2 × 2H, 5′-H), 3.02–3.06 (m,
2 × 2H, Lys-6-H), 3.34–3.41 (m, 2 × 2H, 3-H), 3.51–3.54 (m, 2 × 1H,
1′-Ha), 3.87–3.92 (m, 2 × 1H, 2′-H), 4.01–4.13 (m, 2 × 1H, 1′-Hb),
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4.28–4.34 (m, 2 × 2H, Val-2-H, Lys-2-H), 4.40–4.44 (m, 2 × 1H, Leu-2-
H), 4.95–5.02 (m, 2 × 1H, 1-H) ppm. TLC (CH2Cl2/MeOH, 9:1): Rf =
0.22.
Val-Lys-Ala peptide dithioacetal (27a): General procedure GP4
with 1,3-dioxolane 26a (57.6 mg, 82.1 μmol), boron trifluoride di-
ethyl etherate (1.50 μL, 1.73 mg, 12.2 μmol) and ethanethiol
(0.12 mL, 0.10 g, 1.6 mmol) in CH2Cl2 (6 mL) over 5 d. After 4 d,
additional boron trifluoride diethyl etherate (0.50 μL, 0.58 mg,
4.1 μmol) was added. DIPEA (0.08 mL, 0.06 g, 0.5 mmol) was then
added. Column chromatography (CH2Cl2/MeOH, 95:5), gave 27a as
a colourless solid (40.0 mg, 72 %). 1H NMR (500 MHz, CDCl3): δ =
0.87 (d, J = 6.8 Hz, 3H, Val-4-H), 0.91 (d, J = 6.8 Hz, 3H, Val-4-H), 1.22
(dt, J = 7.4, 0.9 Hz, 6H, 2′-H), 1.33 (d, J = 7.1 Hz, 3H, Ala-3-H), 1.30–
1.37 (m, 2H, Lys-4-H), 1.42 (s, 9H, Boc-OC(CH3)3), 1.46 (s, 9H,
OC(CH3)3), 1.38–1.49 (m, 2H, Lys-5-H), 1.55–1.64 (m, 1H, Lys-3-Ha),
1.68–1.75 (m, 1H, Lys-3-Hb), 1.98–2.03 (m, 2H, 2-H), 2.06–2.12 (m,
1H, Val-3-H), 2.53–2.60 (m, 2H, 1′-Ha), 2.62–2.69 (m, 2H, 1′-Hb), 3.04–
3.08 (m, 2H, Lys-6-H), 3.36–3.42 (m, 1H, 3-Ha), 3.47–3.54 (m, 1H, 3-
Hb), 3.82 (t, J = 7.2 Hz, 1H, 1-H), 4.30–4.33 (m, 1H, Val-2-H), 4.40–
4.41 (m, 1H, Lys-2-H), 4.58–4.64 (m, 1H, Ala-2-H), 5.07 (s, 1H, Boc-
NH), 6.08 (d, J = 7.9 Hz, 1H, Val-NH), 6.58 (s, 1H, Lys-NH), 7.32 (s, 1H,
Ala-NH), 7.49 (s, 1H, 3-NH) ppm. 13C NMR (126 MHz, CDCl3): δ =
14.56 (C-2′), 14.58 (C-2′), 17.91 (Val-C-4), 18.62 (Ala-C-3), 19.19 (Val-
C-4), 22.71 (Lys-C-4), 24.13 (C-1′), 24.34 (C-1′), 28.26 [OC(CH3)3],
28.63 (Boc-OC(CH3)3), 29.78 (Lys-C-5), 31.84 (Val-C-3), 33.12 (Lys-C-
3), 35.67 (C-2), 37.90 (C-3), 40.13 (Lys-C-6), 48.95 (C-1, Ala-C-2), 53.98
(Lys-C-2), 58.43 (Val-C-2), 79.15 (Boc-OC(CH3)3), 81.75 [OC(CH3)3],
156.48 (Boc-C=O), 158.26 (urea-C=O), 172.64 (Ala-C-1), 172.68 (Lys-
C-1), 173.21 (Val-C-1) ppm. HRMS (ESI): calcd. for C31H60N5O7S2
[M + H]+ 678.3929, found 678.3932. IR (ATR): ν̃ = 3281, 2970, 2930,
1725, 1629, 1542, 1366, 1161 cm–1. UV (CHCl3): λmax = 224 nm. TLC
(CH2Cl2/MeOH, 9:1): Rf = 0.46.
Val-Ala-Leu peptide dithioacetal (27b): General procedure GP4
with 1,3-dioxolane 26b (28.6 mg, 48.7 μmol), boron trifluoride di-
ethyl etherate (0.60 μL, 0.69 mg, 4.9 μmol) and ethanethiol (60 μL,
50 mg, 0.81 mmol) in CH2Cl2 (3 mL) over 5 d. After 2 d, additional
boron trifluoride diethyl etherate (0.30 μL, 0.35 mg, 2.5 μmol) was
added. DIPEA (50 μL, 38 mg, 0.29 mmol) was then added. Column
chromatography (CH2Cl2/MeOH, 98:2) gave 27b as a colourless solid
(23.4 mg, 85 %). 1H NMR (500 MHz, CDCl3): δ = 0.86–0.93 (m, 12H,
Val-4-H, Leu-5-H), 1.21 (t, J = 7.4 Hz, 3H, 2′-H), 1.22 (t, J = 7.4 Hz,
3H, 2′-H), 1.28 (d, J = 7.0 Hz, 3H, Ala-3-H), 1.47 (s, 9H, OC(CH3)3),
1.52–1.71 (m, 3H, Leu-3-H, Leu-4-H), 1.96–2.04 (m, 2H, 2-H), 2.04–
2.10 (m, 1H, Val-3-H), 2.55 (q, J = 7.4 Hz, 1H, 1′-Ha), 2.58 (q, J =
7.4 Hz, 1H, 1′-Ha), 2.61–2.69 (m, 2H, 1′-Hb), 3.39–3.52 (m, 2H, 3-H),
3.80 (t, J = 7.2 Hz, 1H, 1-H), 4.30 (dd, J = 8.8, 5.1 Hz, 1H, Val-2-H),
4.53–4.57 (m, 1H, Leu-2-H), 4.60–4.66 (m, 1H, Ala-2-H), 6.26 (d, J =
8.8 Hz, 1H, Val-NH), 6.62 (d, J = 6.5 Hz, 1H, Ala-NH), 7.64 (s, 1H, Leu-
NH), 7.82 (s, 1H, 3-NH) ppm. 13C NMR (126 MHz, CDCl3): δ = 14.57
(C-2′), 14.61 (C-2′), 18.09 (Val-C-4), 19.21 (Val-C-4), 19.89 (Ala-C-3),
22.53 (Leu-C-5), 22.87 (Leu-C-5), 24.16 (C-1′), 24.38 (C-1′), 24.98 (Leu-
C-4), 28.29 [OC(CH3)3], 31.94 (Val-C-3), 35.74 (C-2), 37.97 (C-3), 41.42
(Leu-C-3), 49.05 (C-1), 49.37 (Ala-C-2), 52.06 (Leu-C-2), 58.51 (Val-C-
2), 81.60 [OC(CH3)3], 157.93 (urea-C=O), 172.63 (Leu-C-1), 172.80
(Val-C-1), 174.17 (Ala-C-1) ppm. HRMS (ESI): calcd. for C26H51N4O5S2
[M + H]+ 563.3295, found 563.3293. IR (ATR): ν̃ = 3272, 2963, 1731,
1630, 1543, 1367, 1257, 1145, 712 cm–1. UV (CHCl3): λmax = 220 nm.
TLC (CH2Cl2/MeOH, 9:1): Rf = 0.49.
Ala-Lys-Leu peptide dithioacetal (27c): General procedure GP4
with 1,3-dioxolane 26c (31.8 mg, 44.4 μmol), boron trifluoride di-
ethyl etherate (0.55 μL, 0.63 mg, 4.4 μmol) and ethanethiol (0.05 mL,
0.04 g, 0.7 mmol) in CH2Cl2 (4 mL) over 5 d. After 3 d, additional
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boron trifluoride diethyl etherate (0.28 μL, 0.32 mg, 2.2 μmol) was
added. DIPEA (45 μL, 34 mg, 0.26 mmol) was then added. Column
chromatography (CH2Cl2/MeOH, 98:2) gave 27c as a colourless solid
(22.6 mg, 74 %). 1H NMR (500 MHz, CDCl3): δ = 0.87 (d, J = 6.4 Hz,
3H, Leu-5-H), 0.90 (d, J = 6.4 Hz, 3H, Leu-5-H), 1.22 (t, J = 7.5 Hz,
3H, 2′-H), 1.22 (t, J = 7.4 Hz, 3H, 2′-H), 1.29–1.33 (m, 2H, Lys-4-H),
1.32 (d, J = 7.1 Hz, 3H, Ala-3-H), 1.42 (s, 9H, Boc-OC(CH3)3), 1.46 (s,
9H, OC(CH3)3), 1.42–1.48 (m, 2H, Lys-5-H), 1.51–1.71 (m, 5H, Leu-3-
H, Leu-4-H, Lys-3-H), 1.97–2.02 (m, 2H, 2-H), 2.53–2.60 (m, 2H, 1′-
Ha), 2.64 (q, J = 7.5 Hz, 1H, 1′-Hb), 2.67 (q, J = 7.5 Hz, 1H, 1′-Hb),
3.03–3.07 (m, 2H, Lys-6-H), 3.36–3.43 (m, 1H, 3-Ha), 3.47–3.53 (m,
1H, 3-Hb), 3.82 (t, J = 7.1 Hz, 1H, 1-H), 4.37–4.43 (m, 1H, Ala-2-H),
4.48–4.49 (m, 1H, Lys-2-H), 4.56–4.61 (m, 1H, Leu-2-H), 5.12 (s, 1H,
Boc-NH), 6.17 (d, J = 5.4 Hz, 1H, Ala-NH), 6.69 (s, 1H, Lys-NH), 7.39
(s, 1H, Leu-NH), 7.74 (s, 1H, 3-NH) ppm. 13C NMR (126 MHz, CDCl3):
δ = 14.55 (C-2′), 14.59 (C-2′), 19.62 (Ala-C-3), 22.44 (Leu-C-5), 22.65
(Lys-C-4), 22.90 (Leu-C-5), 24.00 (C-1′), 24.37 (C-1′), 25.01 (Leu-C-4),
28.20 [OC(CH3)3], 28.63 (Boc-OC(CH3)3), 29.80 (Lys-C-5), 33.25 (Lys-
C-3), 35.69 (C-2), 37.92 (C-3), 40.14 (Lys-C-6), 41.21 (Leu-C-3), 49.01
(C-1), 49.41 (Ala-C-2), 51.87 (Leu-C-2), 53.70 (Lys-C-2), 79.10 (Boc-
OC(CH3)3), 81.68 [OC(CH3)3], 156.50 (Boc-C=O), 157.68 (urea-C=O),
172.49 (Leu-C-1), 173.35 (Lys-C-1), 173.70 (Ala-C-1) ppm. HRMS (ESI):
calcd. for C32H62N5O7S2 [M + H]+ 692.4085, found 692.4088. IR (ATR):
ν̃ = 3270, 2970, 2931, 1736, 1628, 1543, 1230, 1162 cm–1. UV (CHCl3):
λmax = 221 nm. TLC (CH2Cl2/MeOH, 9:1): Rf = 0.47.
Val-Lys-Leu peptide dithioacetal (27d): General procedure GP4
with 1,3-dioxolane 26d (46.9 mg, 63.0 μmol), boron trifluoride di-
ethyl etherate (0.78 μL, 0.90 mg, 6.3 μmol) and ethanethiol (70 μL,
59 mg, 0.95 mmol) in CH2Cl2 (4 mL) over 7 d. After 2 d and 4 d,
additional boron trifluoride diethyl etherate (2 × 0.39 μL, 0.45 mg,
3.2 μmol) was added. DIPEA (60 μL, 46 mg, 0.35 mmol) was then
added. Column chromatography (CH2Cl2/MeOH, 98:2) gave 27d as
a colourless solid (30.4 mg, 67 %). 1H NMR (500 MHz, CDCl3): δ =
0.85–0.91 (m, 12H, Val-4-H, Leu-5-H), 1.23 (t, J = 7.4 Hz, 6H, 2′-H),
1.31–1.37 (m, 2H, Lys-4-H), 1.44 (s, 9H, Boc-OC(CH3)3), 1.46 (s, 9H,
OC(CH3)3), 1.46–1.76 (m, 7H, Leu-3-H, Leu-4-H, Lys-3-H, Lys-5-H),
1.95–2.03 (m, 2H, 2-H), 2.05–2.12 (m, 1H, Val-3-H), 2.54–2.61 (m, 2H,
1′-Ha), 2.63–2.70 (m, 2H, 1′-Hb), 3.04–3.13 (m, 2H, Lys-6-H), 3.30–3.37
(m, 1H, 3-Ha), 3.48–3.55 (m, 1H, 3-Hb), 3.82 (t, J = 7.2 Hz, 1H, 1-H),
4.26–4.29 (m, 1H, Lys-2-H), 4.31–4.34 (m, 1H, Val-2-H), 4.39–4.43 (m,
1H, Leu-2-H), 5.06 (s, 1H, Boc-NH), 5.91 (d, J = 7.0 Hz, 1H, Val-NH),
6.35 (s, 1H, Lys-NH), 6.89 (s, 1H, Leu-NH), 7.42 (s, 1H, 3-NH) ppm.
13C NMR (126 MHz, CDCl3): δ = 14.59 (C-2′), 14.60 (C-2′), 17.81 (Val-
C-4), 19.18 (Val-C-4), 22.15 (Leu-C-5), 22.39 (Lys-C-4), 23.01 (Leu-C-
5), 24.06 (C-1′), 24.40 (C-1′), 25.04 (Leu-C-4), 28.26 [OC(CH3)3], 28.64
(Boc-OC(CH3)3), 29.78 (Lys-C-5), 31.89 (Val-C-3), 32.16 (Lys-C-3),
35.62 (C-2), 37.91 (C-3), 39.77 (Lys-C-6), 40.87 (Leu-C-3), 49.03 (C-1),
52.19 (Leu-C-2), 54.31 (Lys-C-2), 58.37 (Val-C-2), 79.27 (Boc-
OC(CH3)3), 81.92 [OC(CH3)3], 156.70 (Boc-C=O), 158.39 (urea-C=O),
172.28 (Leu-C-1), 172.59 (Lys-C-1), 173.41 (Val-C-1) ppm. HRMS (ESI):
calcd. for C34H66N5O7S2 [M + H]+ 720.4398, found 720.4405. IR (ATR):
ν̃ = 3271, 2964, 2931, 1630, 1544, 1366, 1252, 1161 cm–1. UV (CHCl3):
λmax = 220 nm. TLC (CH2Cl2/MeOH, 9:1): Rf = 0.49.
Muraymycin analogue with Val-Lys-Ala peptide unit (28a): Gen-
eral procedure GP6 with aldehyde 14a (3.8 mg, 6.7 μmol) and nu-
cleoside 13[12b] (3.9 mg, 6.7 μmol) in THF (2 mL) After 19 h, Amber-
lyst-15TM (spatula tip) and sodium triacetoxyborohydride (3.5 mg,
17 μmol) were added, and the mixture was further stirred for 21 h.
Column chromatography (CH2Cl2/MeOH, 95:5) gave the fully pro-
tected muraymycin analogue. This was dissolved in 80 % TFA in
water (1.5 mL) and stirred at r.t. for 24 h. The mixture was diluted
with water and the solvent was evaporated under reduced pressure.
The resultant crude product was purified by semipreparative HPLC
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(method 1) and lyophilised to give 28a (bis-TFA salt) as a fluffy
colourless solid (2.4 mg, 39 % over 2 steps). 1H NMR (500 MHz, D2O):
δ = 0.85 (d, J = 6.9 Hz, 3H, Val-4-H), 0.89 (d, J = 6.9 Hz, 3H, Val-4-
H), 1.31 (d, J = 7.3 Hz, 3H, Ala-3-H), 1.38–1.44 (m, 2H, Lys-4-H), 1.60–
1.67 (m, 3H, Lys-5-H, Lys-3-Ha), 1.71–1.78 (m, 1H, Lys-3-Hb), 1.83–
1.89 (m, 2H, 2′′-H), 2.04–2.11 (m, 1H, Val-3-H), 2.16–2.22 (m, 1H, 5′-
Ha), 2.33–2.38 (m, 1H, 5′-Hb), 2.95 (t, J = 7.6 Hz, 2H, Lys-6-H), 3.02
(dd, J = 7.6, 7.6 Hz, 2H, 1′′-H), 3.18–3.29 (m, 2H, 3′′-H), 3.74 (dd, J =
6.5, 6.5 Hz, 1H, 6′-H), 3.97 (d, J = 5.3 Hz, 1H, Val-2-H), 4.01–4.04 (m,
1H, 3′-H), 4.04–4.06 (m, 1H, Lys-2-H), 4.09–4.13 (m, 1H, 4′-H), 4.15
(d, J = 7.3 Hz, 1H, Ala-2-H), 4.37 (dd, J = 5.7, 3.7 Hz, 1H, 2′-H), 5.71
(d, J = 3.7 Hz, 1H, 1′-H), 5.83 (d, J = 8.1 Hz, 1H, 5-H), 7.62 (d, J =
8.1 Hz, 1H, 6-H) ppm. 13C NMR (126 MHz, D2O): δ = 16.28 (Ala-C-3),
16.82 (Val-C-4), 18.60 (Val-C-4), 21.89 (Lys-C-4), 25.60 (C-2′′), 26.12
(Lys-C-5), 30.12 (Val-C-3), 30.74 (Lys-C-3), 32.96 (C-5′), 35.80 (C-3′′),
39.11 (Lys-C-6), 44.10 (C-1′′), 49.88 (Ala-C-2), 53.91 (Lys-C-2), 59.62
(Val-C-2), 60.31 (C-6′), 72.55 (C-2′), 72.80 (C-3′), 80.04 (C-4′), 91.63
(C-1′), 102.04 (C-5), 116.23 (q, 1JCF = 292 Hz, F3CCOO), 142.73 (C-6),
151.33 (C-2), 159.46 (urea-C=O), 162.99 (q, 2JCF = 35.5 Hz, F3CCOO),
166.16 (C-4), 172.49 (C-7′), 175.28 (Ala-C-1), 175.34 (Lys-C-1), 178.01
(Val-C-1) ppm. 19F NMR (376 MHz, D2O): δ = –75.60 (TFA-CF3) ppm.
HRMS (ESI): calcd. for C29H49N8O12 [M + H]+ 701.3464, found
701.3470. IR (ATR): ν̃ = 3306, 3062, 2967, 1672, 1559, 1428, 1201,
1133, 800, 722 cm–1. UV (H2O): λmax = 260 nm. HPLC (method 1):
tR = 19.6 min.
Muraymycin analogue with Val-Ala-Leu peptide unit (28b): Gen-
eral procedure GP6 with aldehyde 14b (8.8 mg, 19 μmol) and nucle-
oside 13[12b] (14 mg, 24 μmol) in THF (3 mL). After 18 h, Amberlyst-
15TM (spatula tip) and sodium triacetoxyborohydride (8.5 mg,
40 μmol) were added, and the mixture was further stirred for 23 h.
Column chromatography (CH2Cl2/MeOH, 98:2 → 95:5) gave the fully
protected muraymycin analogue. This was dissolved in 80 % TFA in
water (1.5 mL) and stirred at r.t. for 24 h. The mixture was diluted
with water and the solvent was evaporated under reduced pressure.
The resultant crude product was purified by semipreparative HPLC
(method 2) and lyophilised to give 28b (TFA salt) as a fluffy colour-
less solid (8.9 mg, 58 % over 2 steps). 1H NMR (500 MHz, D2O): δ =
0.84 (d, J = 6.2 Hz, 3H, Leu-5-H), 0.89 (d, J = 6.2 Hz, 3H, Leu-5-H),
0.90 (d, J = 6.9 Hz, 3H, Val-4-H), 0.94 (d, J = 6.9 Hz, 3H, Val-4-H), 1.31
(d, J = 7.2 Hz, 3H, Ala-3-H), 1.52–1.64 (m, 3H, Leu-3-H, Leu-4-H),
1.86–1.92 (m, 2H, 2′′-H), 2.07–2.16 (m, 1H, Val-3-H), 2.27–2.34 (m,
1H, 5′-Ha), 2.42–2.47 (m, 1H, 5′-Hb), 3.07 (t, J = 7.7 Hz, 2H, 1′′-H),
3.15–3.24 (m, 1H, 3′′-Ha), 3.28–3.33 (m, 1H, 3′′-Hb), 4.01 (dd, J = 6.3,
6.3 Hz, 1H, 6′-H), 4.05–4.10 (m, 1H, 3′-H), 4.06 (d, J = 5.4 Hz, 1H, Val-
2-H), 4.09 (d, J = 7.2 Hz, 1H, Ala-2-H), 4.13–4.17 (m, 1H, 4′-H), 4.20–
4.23 (m, 1H, Leu-2-H), 4.41 (dd, J = 5.7, 3.8 Hz, 1H, 2′-H), 5.72 (d, J =
3.8 Hz, 1H, 1′-H), 5.85 (d, J = 8.1 Hz, 1H, 5-H), 7.62 (d, J = 8.1 Hz,
1H, 6-H) ppm. 13C NMR (126 MHz, D2O): δ = 16.95 (Ala-C-3), 17.06
(Val-C-4), 18.53 (Val-C-4), 20.71 (Leu-C-5), 22.19 (Leu-C-5), 24.45
(Leu-C-4), 25.67 (C-2′′), 30.03 (Val-C-3), 32.60 (C-5′), 36.00 (C-3′′),
39.51 (Leu-C-3), 44.27 (C-1′′), 50.40 (Ala-C-2), 52.65 (Leu-C-2), 58.91
(C-6′), 58.94 (Val-C-2), 72.66 (C-2′), 73.00 (C-3′), 79.79 (C-4′), 91.89
(C-1′), 102.27 (C-5), 142.88 (C-6), 151.47 (C-2), 159.45 (urea-C=O),
166.25 (C-4), 171.53 (C-7′), 175.15 (Leu-C-1), 175.73 (Ala-C-1, Val-C-
1) ppm. 19F NMR (376 MHz, D2O): δ = –75.60 (TFA-CF3) ppm. HRMS
(ESI): calcd. for C29H48N7O12 [M + H]+ 686.3355, found 686.3355. IR
(ATR): ν̃ = 3306, 2963, 1655, 1560, 1466, 1199, 1135, 721, 552 cm–1.
UV (H2O): λmax = 260 nm. HPLC (method 2): tR = 19.4 min.
Muraymycin analogue with Ala-Lys-Leu peptide unit (28c):
General procedure GP6 with aldehyde 14c (6.6 mg, 11 μmol) and
nucleoside 13[12b] (10 mg, 17 μmol) in THF (3 mL). After 18 h, Am-
berlyst-15TM (spatula tip) and sodium triacetoxyborohydride
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(4.8 mg, 23 μmol) were added, and the mixture was further stirred
for 22 h. Column chromatography (CH2Cl2/MeOH, 98:2 → 95:5) gave
the fully protected muraymycin analogue. This was dissolved in
80 % TFA in water (1.5 mL) and stirred at r.t. for 24 h. The mixture
was diluted with water and the solvent was evaporated under re-
duced pressure. The resultant crude product was purified by semi-
preparative HPLC (method 2) and lyophilised to give 28c (bis-TFA
salt) as a fluffy colourless solid (4.9 mg, 46 % over 2 steps). 1H NMR
(500 MHz, D2O): δ = 0.87 (d, J = 6.1 Hz, 3H, Leu-5-H), 0.93 (d, J =
6.1 Hz, 3H, Leu-5-H), 1.40 (d, J = 7.3 Hz, 3H, Ala-3-H), 1.42–1.49 (m,
2H, Lys-4-H), 1.55–1.73 (m, 6H, Leu-3-H, Leu-4-H, Lys-5-H, Lys-3-Ha),
1.76–1.83 (m, 1H, Lys-3-Hb), 1.89–1.95 (m, 2H, 2′′-H), 2.27–2.34 (m,
1H, 5′-Ha), 2.44–2.48 (m, 1H, 5′-Hb), 3.00 (t, J = 7.6 Hz, 2H, Lys-6-H),
3.06 (dd, J = 7.9, 7.9 Hz, 2H, 1′′-H), 3.23–3.35 (m, 2H, 3′′-H), 3.96 (dd,
J = 6.4, 6.4 Hz, 1H, 6′-H), 4.08–4.13 (m, 2H, 3′-H, Lys-2-H), 4.16–4.22
(m, 2H, 4′-H, Ala-2-H), 4.20 (d, J = 7.3 Hz, 1H, Ala-2-H), 4.25–4.28 (m,
1H, Leu-2-H), 4.44 (dd, J = 5.6, 3.8 Hz, 1H, 2′-H), 5.76 (d, J = 3.8 Hz,
1H, 1′-H), 5.89 (d, J = 8.1 Hz, 1H, 5-H), 7.66 (d, J = 8.1 Hz, 1H, 6-H)
ppm. 13C NMR (126 MHz, D2O): δ = 16.72 (Ala-C-3), 20.67 (Leu-C-5),
22.11 (Leu-C-5), 22.15 (Lys-C-4), 24.47 (Leu-C-4), 25.68 (C-2′′), 26.31
(Lys-C-5), 30.81 (Lys-C-3), 32.76 (C-5′), 36.01 (C-3′′), 39.29 (Lys-C-6),
39.48 (Leu-C-3), 44.31 (C-1′′), 49.30 (Ala-C-2), 52.65 (Leu-C-2), 54.26
(Lys-C-2), 59.42 (C-6′), 72.66 (C-2′), 73.00 (C-3′), 79.96 (C-4′), 91.88
(C-1′), 102.28 (C-5), 115.26–117.57 (m, F3CCOO), 142.91 (C-6), 151.49
(C-2), 159.27 (urea-C=O), 166.26 (C-4), 171.84 (C-7′), 175.01 (Leu-C-
1), 175.57 (Lys-C-1), 177.98 (Ala-C-1) ppm. 19F NMR (376 MHz, D2O):
δ = –75.60 (TFA-CF3) ppm. HRMS (ESI): calcd. for C30H51N8O12 [M +
H]+ 715.3621, found 715.3628. IR (ATR): ν̃ = 3294, 2960, 1670, 1558,
1430, 1200, 1133, 800, 722 cm–1. UV (H2O): λmax = 261 nm. HPLC
(method 2): tR = 28.3 min.
Reference muraymycin analogue with Val-Lys-Leu peptide unit
(28d):[10i] General procedure GP6 with aldehyde 14d (8.5 mg,
14 μmol) and nucleoside 13[12b] (10 mg, 17 μmol) in THF (3 mL).
After 18 h, Amberlyst-15TM (spatula tip) and sodium triacetoxyboro-
hydride (6.3 mg, 30 μmol) were added, and the mixture was further
stirred for 20 h. Column chromatography (CH2Cl2/MeOH, 98:2 →
95:5) gave the fully protected muraymycin analogue. This was dis-
solved in 80 % TFA in water (2 mL) and stirred at r.t. for 23 h. The
mixture was diluted with water and the solvent was evaporated
under reduced pressure. The resultant crude product was purified
by semipreparative HPLC (method 2) and lyophilised to give 28d
(bis-TFA salt) as a fluffy colourless solid (7.0 mg, 52 % over 2 steps).
1H NMR (500 MHz, D2O): δ = 0.84 (d, J = 6.1 Hz, 3H, Leu-5-H), 0.89
(d, J = 6.1 Hz, 3H, Leu-5-H), 0.90 (d, J = 6.9 Hz, 3H, Val-4-H), 0.94 (d,
J = 6.9 Hz, 3H, Val-4-H), 1.36–1.47 (m, 2H, Lys-4-H), 1.50–1.70 (m,
6H, Leu-3-H, Leu-4-H, Lys-5-H, Lys-3-Ha), 1.73–1.80 (m, 1H, Lys-3-Hb),
1.86–1.92 (m, 2H, 2′′-H), 2.10–2.17 (m, 1H, Val-3-H), 2.25–2.31 (m,
1H, 5′-Ha), 2.40–2.45 (m, 1H, 5′-Hb), 2.97 (t, J = 7.7 Hz, 2H, Lys-6-H),
3.06 (dd, J = 8.1, 7.3 Hz, 2H, 1′′-H), 3.20–3.31 (m, 2H, 3′′-H), 3.93 (dd,
J = 6.4, 6.4 Hz, 1H, 6′-H), 4.05–4.08 (m, 2H, 3′-H, Val-2-H), 4.09–4.11
(m, 1H, Lys-2-H), 4.12–4.16 (m, 1H, 4′-H), 4.21–4.24 (m, 1H, Leu-2-H),
4.41 (dd, J = 5.9, 3.8 Hz, 1H, 2′-H), 5.73 (d, J = 3.8 Hz, 1H, 1′-H), 5.85
(d, J = 8.1 Hz, 1H, 5-H), 7.63 (d, J = 8.1 Hz, 1H, 6-H) ppm. 13C NMR
(126 MHz, D2O): δ = 17.04 (Val-C-4), 18.56 (Val-C-4), 20.72 (Leu-C-
5), 22.10 (Lys-C-4), 22.16 (Leu-C-5), 24.46 (Leu-C-4), 25.70 (C-2′′),
26.32 (Lys-C-5), 30.02 (Val-C-3), 30.83 (Lys-C-3), 32.79 (C-5′), 36.02
(C-3′′), 39.30 (Lys-C-6), 39.58 (Leu-C-3), 44.32 (C-1′′), 52.64 (Leu-C-2),
54.14 (Lys-C-2), 58.94 (Val-C-2), 59.44 (C-6′), 72.66 (C-2′), 73.00
(C-3′), 79.97 (C-4′), 91.88 (C-1′), 102.29 (C-5), 142.90 (C-6), 151.48 (C-
2), 159.57 (urea-C=O), 166.25 (C-4), 171.84 (C-7′), 174.97 (Leu-C-1),
175.47 (Lys-C-1), 176.78 (Val-C-1) ppm. 19F NMR (376 MHz, D2O): δ =
–75.59 (TFA-CF3) ppm. MS (ESI): calcd. for C32H55N8O12 [M + H]+
743.39, found 743.39. HPLC (method 2): tR = 22.3 min.
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Overexpression of MraY from S. aureus: The overexpression of
MraY was performed as described before.[10h,10i,17d]
Fluorescence-based MraY assay: The MraY assay was performed
as described before.[10h,10i,17d]
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